Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksGenincode Regulatory News (GENI)

Share Price Information for Genincode (GENI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.25
Prev. Close: 5.25

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

25 Nov 2021 07:00

RNS Number : 5213T
GENinCode PLC
25 November 2021
 

25 November 2021

 

GENinCode Plc

("GENinCode" or the "Company")

 

Trading and progress update

 

GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, provides the following trading and progress update ahead of its financial year end on 31 December 2021.

 

Following the successful admission to AIM in July 2021 and ramp-up in operations over the second half of this financial year, the Company is now moving towards a number of important milestones which will drive its growth and profile over the coming years.

 

These milestones are expected to accelerate the Company's commercial programme to lift the Standard of Care for cardiovascular disease ("CVD") by enabling more precise patient diagnosis and risk stratification to improve preventative care.

 

The Company is focused on delivering the plans set out in its admission document, especially around the preparation for the US launch of Cardio inCode® in 2022. In summary:

 

· Cardio inCode® de-novo submission for US regulatory approval with the FDA - The Company continues to have constructive and ongoing discussions with the FDA and is finalising its de-novo application. The de-novo submission is expected to be filed by the end of this year.

 

· Breakthrough Device Designation (FDA) for Cardio inCode® - Discussions continue to progress with the FDA to advance Cardio inCode® as a 'Breakthrough device'. Discussions have been extended partly due to FDA workload, but also resulting from a detailed assessment of GENinCode's CVD prognostic device which, in turn, has given the Company confidence to file its de-novo submission earlier than it might otherwise have planned. The Company remains well placed to complete this process over the coming months.

 

· Cardio inCode® launch programme with EVERSANA Life Sciences LLC for introduction to US market in 2022 - The Company is working closely with its new collaborative partner EVERSANA to finalise the programme for the Cardio inCode® launch, expected in H2 2022. The EVERSANA health team comprises of a multi-disciplined group of experts covering market access, reimbursement, regulatory and field sales, supporting the commercial development of the Company's US programme.

 

· CPT coding for Cardio inCode® and commencement of CMS payer and reimbursement discussions - The Company is now finalising the CPT-PLA coding draft and expects to file its coding application in Q1 2022. CMS discussions are anticipated to commence regarding reimbursement in the New Year.

 

· Royal Brompton & Harefield set-up and commissioning for Lipid inCode® hypercholesterolemia testing - The Company has successfully completed the validation of its hypercholesterolemia testing at the Royal Brompton Hospital Genetic Labs in London and expects to start commercial testing with UK private payers and NHS Academic Health Science Networks (AHSNs) over the coming month.

 

· Indiana University and New York Presbyterian collaborations - The Company is finalising collaborative agreements with both these flagship facilities to advance the clinical diagnosis of CVD. Initial collaborative work will focus on the introduction of Cardio inCode® and Thrombo inCode® products for CVD and COVID-19 clinical study assessment.

 

· US CLIA (Clinical Laboratory Improvement Amendments) authorised testing facility - Discussions are ongoing with a number of CLIA labs to implement Cardio inCode® genetic test service delivery for the US market. The Company expects to announce further CLIA developments over the coming months.

 

· UK Hypercholesterolemia study for Lipid inCode® - The NHS 'Evaluation of novel rapid genomic test (Lipid inCode®) including polygenic risk scores for the diagnosis and management of Familial Hypercholesterolaemia' study is due to report its findings in the international journal 'Global Cardiology Sciences and Practice' over the coming months. The publication is currently with the editorial board.

 

· First COVID-19 Thrombo inCode® evaluation study for genetic predisposition to thrombosis - St. Pau hospital, Barcelona - Preliminary data from the Company's first COVID-19 study indicates that there is a correlation between inherited thrombophilia (blood clotting) and more severe complications for individuals suffering with COVID-19. Preliminary data from a second COVID-19 study is anticipated over the coming months.

 

· Trading outlook - Over the H2 2021 reporting period the Company has seen increased EU product revenues in line with market guidance.

 

Matthew Walls, CEO of GENinCode Plc said: "Since admission in July, we have made solid progress in delivering the key milestones set out in our business plan. The business is developing swiftly and we are increasing our investment in key resources and expertise to take advantage of growth opportunities opening to us and strengthening our Board to include a greater US market presence, awareness, and expertise to reflect our long-term goals. We look forward to updating the market and our shareholders in due course."

 

 

For further information please contact:

 

GENinCode Plc

www.genincode.com or via Walbrook PR

Matthew Walls, CEO

Paul Foulger, CFO

 

Stifel Nicolaus Europe Limited (Nomad and Joint Broker)

Tel: +44 (0)20 7710 7600

Alex Price / Ben Maddison / Richard Short

 

Cenkos Securities Plc (Joint Broker)

 

Tel: +44 (0)20 7397 8900

Giles Balleny

Dale Bellis / Michael Johnson (Sales)

Walbrook PR Limited

 

Tel: 020 7933 8780 or genincode@walbrookpr.com

Anna Dunphy / Paul McManus / Louis Ashe-Jepson

 

 

About GENinCode plc

 

GENinCode plc is engaged in the risk assessment, prediction and prevention of cardiovascular disease ("CVD"). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company's products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.

 

The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. Approximately €50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is also targeting the UK and US.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPGPAGUPGGBC
12
Date   Source Headline
25th Sep 20247:00 amRNSHalf-year Report
20th Sep 20247:36 amRNSCollaboration with The Family Heart Foundation
9th Sep 20247:00 amRNSNotice of Results
28th Aug 20247:00 amRNSCARDIO inCode-Score presentation
27th Jun 20244:02 pmRNSResult of AGM
5th Jun 20245:17 pmRNSPosting of Annual Report and Notice of AGM
3rd Jun 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSNotice of Results
1st May 20247:00 amRNSCARDIO inCode-Score presentation
26th Apr 20242:30 pmRNSGrant of Options & Surrender of Existing Options
4th Apr 202410:44 amRNSCARDIO inCode-Score® US study publication
21st Mar 202410:58 amRNSNew NICE Guidance for Ovarian Cancer
9th Feb 202410:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSHolding(s) in Company
11th Jan 20242:49 pmRNSHolding(s) in Company
11th Jan 20242:30 pmRNSHolding(s) in Company
9th Jan 20241:30 pmRNSResult of GM and Total Voting Rights
28th Dec 20237:00 amRNSResult of Retail Offer
21st Dec 20236:25 pmRNSResult of Placing and Subscription
21st Dec 20234:59 pmRNSRetail Offer
21st Dec 20234:55 pmRNSPlacing and Subscription
29th Nov 20237:10 amRNSCARDIO inCode-Score 510(k) FDA submission update
29th Nov 20237:00 amRNSChange of Adviser
12th Oct 20237:00 amRNSShareSoc investor presentation
20th Sep 20237:00 amRNSHalf-year Report
13th Sep 20237:00 amRNSNotice of Results
30th Aug 20237:00 amRNSPresentation at European Society of Cardiology
16th Aug 202310:27 amRNSCARDIO inCode 510k filing
19th Jul 20237:00 amRNSCollaboration with US healthcare provider
30th Jun 20234:03 pmRNSResult of AGM
8th Jun 20231:31 pmRNSNotice of AGM and posting of Annual Report
6th Jun 20237:00 amRNSFinal Results
5th Jun 20237:00 amRNSNotice of Results
22nd May 20237:00 amRNSCARDIO inCode be presented at conference
15th May 20237:00 amRNSCollaboration with University Clinic Dresden
2nd May 20237:00 amRNSNHS LIPID inCode testing implementation
3rd Apr 20237:00 amRNSCARDIO InCode CPT PLA Code
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20237:00 amRNSApproval of California state license
22nd Nov 20222:07 pmRNSIssue of Share Options
3rd Nov 20227:00 amRNSBritish Medical Journal publication
10th Oct 20226:23 pmRNSHolding(s) in Company
27th Sep 20227:00 amRNSHalf-year report
7th Sep 20227:00 amRNSNotice of results
26th Jul 20227:00 amRNSNHS implementation of Lipid inCode testing
23rd Jun 20222:37 pmRNSResult of AGM
23rd May 20224:06 pmRNSPosting of Annual Report and Notice of AGM
17th May 20227:00 amRNSFinal Results
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Free Investment Tools

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.